Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.38 |
| ▸ | NPY1R | P25929 | 9/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.38 |
| ▸ | NPY2R | P49146 | 5/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10082825 | 0.86 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL24306834 | 0.83 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL25148125 | 0.82 | C3AR1 (0.35) | SIRT5ALB | |
| SCHEMBL16299579 | 0.82 | NOD1 (0.32) | SIRT5 | |
| SCHEMBL6382960 | 0.81 | NPY4R (0.42) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12359232 | 0.80 | NPY4R (0.37) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL1934309 | 0.79 | SIRT5 (0.49) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL24900018 | 0.79 | SIRT5 (0.49) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL8120411 | 0.79 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT5 | |
| SCHEMBL1388278 | 0.79 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2RSIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859494-B2 | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament | SANOFI (FR) | 2014-10-14 | — | — | US | disclosed |
| US-8344004-B2 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-01-01 | — | — | US | disclosed |
| US-8148375-B2 | (Cyclopropylphenyl)phenyloxamides, method for the production thereof, and use of same as a medicament | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | SANOFI (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS (FR) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004187-A1 | SPIROCYCLICALLY SUBSTITUTED 1,3-PROPANE DIOXIDE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF AS A MEDICAMENT | REN, PKD1, AKR1C3 | NPY4R 369/4885NPY1R 153/4885NPY5R 660/4885 |
| US-20110224263-A1 | Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals | PPARD, PPARG, PPARA | NPY4R 1182/4885NPY1R 929/4885NPY5R 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.